Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy.
What makes Scandion Oncology an attractive company for investors?
- Limited investment horizon: Clinical Phase II studies will be completed within few years after investment.
- Potential high return: Detailed analyses from Cortris show that the current market for the chosen indications is more than EUR 4 billion in annual peak sales.
- Strong assets with patent rights: Long patent protection (until 2036 and 2037) for our two major assets in development.
- High unmet medical needs: More than 18 million new cases of cancer every year on a worldwide scale. Half of all patients who receive chemotherapy become resistant.
- Experienced management team: Our executive team includes a CEO with more than 20 years of biotech and pharma experience and a CSO who has authored more than 70 publications, the majority focusing on translational cancer research, biomarkers and drug resistance.
- Robust pipeline: Scandion Oncology has two major assets under development, SCO-101 and SCO-201, and more than 800 analogues for the future. The target indications for the analogues are solid tumors.
- Strong clinical data: Our lead compound SCO-101 has successfully passed four Phase I trials in healthy volunteers without showing toxicity.
- Ongoing clinical Phase I and II studies: Our lead compound SCO-101 is currently in two clinical studies; Phase II (CORIST) in metastatic colorectal cancer and Phase Ib (PANTAX) in pancreatic cancer.
- Potential for first-in-class: There are currently no drugs on the market targeting anti-cancer drug resistance, and SCO-101 has the potential of becoming first in this class of treatments.
- Multiple indications: In addition to our lead compound SCO-101 targeting metastatic colorectal cancer and pancreatic cancer, we are developing SCO-201, which will target other solid tumors.